IM Cannabis Corp. (IMCC) vs Redhill Biopharma Ltd. (RDHL)

IM Cannabis Corp. and Redhill Biopharma Ltd. are both Drug Manufacturers Specialty & Generic companies. Redhill Biopharma Ltd. is the larger, with a market value of $3.2M against $2.0M — 1.7× the size. IM Cannabis Corp. grew revenue faster over the last twelve months: −12.0% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −38.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, IM Cannabis Corp. leads on 9 and Redhill Biopharma Ltd. on 7.

Valuation

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.03 0.32 2.25
P/B n/m n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m n/m 12.29
EV/Sales 0.02 0.30 2.56
Earnings yield (2,710.65%) (122,133.34%) (2.99%)
Free cash flow yield (55.53%) (909.75%) 0.00%

Profitability

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Gross margin 12.62% 35.16% 53.94%
Operating margin (32.88%) 0.00% 0.00%
Net margin (38.92%) 25.20% 0.00%
Free cash flow margin (1.47%) 0.00% 0.00%
Return on equity 2,280.06% 0.00% (0.40%)
Return on assets (54.20%) 0.00% (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (11.97%) (61.93%) 10.01%
EPS growth (last fiscal year) 41.95% 97.91% —
Revenue growth, 5-year CAGR 26.99% (66.15%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Debt to equity (0.12) 0.00 0.05
Current ratio 0.56 0.56 2.31
Net debt to EBITDA 0.18 0.53 0.85

Dividend

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric IMCC RDHL Drug Manufacturers Specialty & Generic median
Market cap 1.95m 3.22m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack